MDS chromosome and gene anomaly detection probe, CEPX/CEPY (CE-IVD)
Catalog No : FP-011-6
513.00€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | MDS chromosome and gene anomaly detection probe, CEPX/CEPY (CE-IVD) | ||
|---|---|---|---|
| Catalog No | FP-011-6 | ||
| Supplier’s Catalog No | FP-011-6 | ||
| Supplier | Wuhan Healthcare Biotech | ||
| Source antigen | CEPX | ||
| Reactivity | CEPX | ||
| Cross reactivity | None | ||
| Applications | Fluorescence In Situ Hybridization (FISH) | ||
| Molecular weight | N/A | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Molecular diagnostic grade | ||
| Purity | N/A | ||
| Form | Liquid | ||
| Reactivity life | 12 months when stored properly according to instructions | ||
| Note | For Professional In Vitro diagnostics | ||
| Description | Among the common chromosomal abnormalities in MDS patients, some chromosomal abnormalities have specific diagnostic value. Some patients with simple +8, 20q- or Y- are effective in immunosuppressive therapy, karyotyping is also of great value in the classification, treatment and prognosis of MDS, such as single Y-, 5q- or 20q-MDS Patients had a better prognosis, and patients with complex chromosomal abnormalities (≥3 abnormalities) or chromosome 7 abnormalities had a poor prognosis, and other abnormal patients had a moderate prognosis. NCCN and the “Chinese Expert Consensus for the Diagnosis and Treatment of Myelodysplastic Syndrome (2014 Edition)” recommend that all patients suspected of having MDS should have a chromosomal test, and fluorescent in situ hybridization probes (commonly abnormal sets of probes) are recommended. Abnormalities are important for the diagnosis, treatment, and prognosis of MDS. | ||
© 2020 Imugex All Rights Reserved